t
On 2 January 2026, Oxford Biomedica PLC filed a period of return for its 2015 Employee Share Option Scheme, 2015 and 2024 Long Term Incentive Plan, 2015 and 2024 Deferred Bonus Plan, and Sharesave Scheme, covering the period from 1 July 2025 to 31 December 2025. During this six-month period, the company issued or allotted a total of 694,854 securities across these four schemes. At the end of the period, the unallotted balances were 267,036, 628,075, 393,913, and 148,676 securities, respectively.
| Date | 2 Jan 2026 |
| Time | 07:00:05 |
| Category | Capital structure |
| ID | 2000N |
|
Name of applicant: |
OXFORD BIOMEDICA PLC |
|||
|
Name of scheme: |
2015 Employee Share Option Scheme |
|||
|
Period of return: |
From: |
1 July 2025 |
To: |
31 December 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
280,836 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
13,800 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
267,036 |
|||
|
|
|
|
|
|
|
Name of applicant: |
OXFORD BIOMEDICA PLC |
|||
|
Name of scheme: |
2015 and 2024 Long Term Incentive Plan |
|||
|
Period of return: |
From: |
1 July 2025 |
To: |
31 December 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
990,229 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
362,154 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
628,075 |
|||
|
|
|
|
|
|
|
Name of applicant: |
OXFORD BIOMEDICA PLC |
|||
|
Name of scheme: |
2015 and 2024 Deferred Bonus Plan |
|||
|
Period of return: |
From: |
1 July 2025 |
To: |
31 December 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
522,449 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
128,536 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
393,913 |
|||
|
|
|
|
|
|
|
Name of applicant: |
OXFORD BIOMEDICA PLC |
|||
|
Name of scheme: |
Sharesave Scheme |
|||
|
Period of return: |
From: |
1 July 2025 |
To: |
31 December 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
339,040 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
190,364 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
148,676 |
|||
|
48 |
|
|||
|
Name of contact: |
Natalie Walter, Chief Legal Officer and Group Company Secretary |
|
Telephone number of contact: |
01865 783000 |
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.